FXR activity, which is inversely related to severity of steatosis in patients with NAFLD (60), downregulates Srebp1 and, indirectly, Cyp7a1 (56, 60). The gene discussed is CYP7A1; the disease is metabolic dysfunction-associated steatotic liver disease.